Overview

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Status:
Not yet recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Criterium, Inc.
Collaborators:
Novartis
Seagen Inc.
Treatments:
Fulvestrant
Tucatinib